Interim report
Page 1
To, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai -400001, India Script Code: 543963 Subject: Outcome of the Board Meeting held on Monday, 10 November 2025 and Submission of the Unaudited Financial Results and Limited Review Report on Financial Result for the half year ended on 30th September, 2025 Ref: Regulation 30, 32, 33 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with corresponding circulars and notifications issued thereunder. Dear Sir/ madam, With reference to the subject matter and pursuant to the Regulation 30 , 32 & 33 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), we would like to inform you that the Board of Directors of the Company at its meeting held today i.e Monday, 10 November 2025, at at 5th Floor, Sakar 4, Opp. MJ Library, Ashram Road, Paldi, Ellisbridge, Ahmedabad - 380006, Gujarat, India inter alia, has considered and approved the following: 1. Approval of Standalone Unaudited Financial Result for the Half Year ended on 30th September, 2025 as per Regulation 33 of the SEBI (LODR) Regulations, 2015 along with Limited Review report. 2. Take a note of Auditor Certificate received under Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019 The meeting was commenced at 1 1:30 a.m. and concluded at 1 1:55 p.m. Kindly take the above on record and oblige. Thanking You. FOR SHELTER PHARMA LIMITED ___________________________________________ MUSTAQIM NISARAHMED SABUGAR DIN: 01456841 MANAGING DIRECTOR Date: 10 November 2025 Place: Ahmedabad Enclosure: Financials & Auditor Certificate under Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019
Page 2
Ref. No. : ~ IND IA Mendajiwala & Co. Chartered Accountant CA Sahel N. Mendajiwala M. 98 98 98 5702 Date: Independent Auditor's Review Report on Unaudited Standalone Financial Results of the SHELTER PHARMA LIMITED for the half year ended on 301h September, 2025 under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. To, The Board of Directors of Shelter Pharma Limited Opinion We have reviewed the accompanying standalone unaudited financial results of SHELTER PHARMA LIMITED(the'.'Company")(CIN : L24233GJ2007PLCOS1956)for the half year ended on 301h September, 2025 ("The Financial Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25 'Interim Financial Reporting' ('AS 25'), prescribed under Section 133 of the Companies Act,2013, as amended, read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) regulations, 2015, as amended (the SEBI Listing Regulations'). Our responsibility is to issue a report on the Statement based on our review. Our responsibility is to express a conclusion on the statement based on our review. Scope of our review We conducted our review of the statement in accordance with the Standards on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by ICAI. A review of statement consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. Conclusion Based -on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, 'prepared in accordance with the recognition and measurement principles laid down in the aforesaid accounting standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement. 539, 540, Sheetal Varsha, Mahavir Business Park, Jamalpur Cross Road, Behrampura, Ahmedabad -380 022. Phone: 079-25353444 E-mail: mendajiwala1011@yahoo.com
Page 3
Our conclusion is not modified in respect of these matters . For, Mendajiwala & Co. Proprieto Membership No.: 146324 UDIN: 2S°1Y b32-lf e,MG-'(1-0 ,043 Date: 101h Nov, 2025 Place: Ahmedabad ...
Page 4
SHELTER PHARMA LIMITED CIN NO.: L24233GJ2007PLC051956 Standalone Statement of Assets and Liabilites as on September 30,2025 (Amount In Lakhs) Particulars I. EQUITY AND LIABILITIES (1) Shareholder's Funds (a) Share Capital (b) Reserves and Surplus (c) Money Received against share warrants (2) Non-Current Liabilities (a) Long-Term Borrowings (b) Deferred Tax Liabilities (Net) ( c) Other Loqg Term liabilities ( d) Long term Proivisions (3) Current Liabilities (a) Short-Term Borrowings (b) 1. Trade Payables - others 2. Trade Payables - MSME (c) Other Current Liabilities ( d) Short-Term Provisions Total Equity & Liabilities II.ASSETS (1) Non-Current Assets (a) Plant, Porperty & Equipments and Intangible Assets _ (i) Plant, Porperty & Equipments (ii) Intangible Assets (b) N,on-current Investments (c) Deferred tax a~sets (net) ( d) Long term loans and advances (e) Other Non-Current Assets (2) Current Assets (a) Current investments (b) Inventories (c) Trade receivables (d) Cash and cash Equivalents (e) Short-term loans and advances (f) Other Curreht Assets Tota~ Assets For Shelter Pharma Limited Mustaqim N Sabugar Chairmain & Managing Director DIN: 01456841 Place: Ahmedabad Date: 10/11/2025 For the period ended on 30.09.2025 (Un Audited) 1,155.98 3,561.47 1,350.84 84.28 5.48 37.68 79.54 - 39.95 374.33 6,689.54 680.59 0.98 67.63 4.40 1,707 .90 1,674 .76 1,093.63 527.96 773.93 157 .78 6,689.54 Shakil N Sabugar Whole Time Director DIN: 01474868 For the year ended on 31.03.2025 (Audited) 1,155 .98 3,116.08 93.16 5.48 - # 11.25 125 .07 - 6.80 319.74 4,833.55 595 .14 1.00 67.63 3.17 838 .75 1,289 .52 947.46 341.99 571.71 177 .19 4,833.55
Page 5
SHELTER PHARMA LIMITED c~® CIN NO.: L24233GJ2007PLC051956 ~ - Statement of Standalone UnAudited Financial Result for the half year ended on September,30 2025 (Amount In Lakhs Except Shares Price) Half Year/ Period ended on Year Ended on Sr. No Particulars 30.09.2025 31.03.2025 30.09.2024 31.03.2025 (Un-Audited) (Audited) (Un-Audited) (Audited) Income I Revenue from operations 3,329.29 2,660 ,35 2,405.67 5,066.02 II Other Income 0.47 0.34 0.21 0.55 III Total Income fl +II) 3,329,75 2,660.69 2,405.88 5,066.56 IV Expenses (a) Cost of Material Consumed 2,490.11 1,938.37 1,776.98 3,715.35 (b) Purchases of Stock-in-Trade ( c) Changes in inventories of finished goods work-in-progress 7.05 -14.92 2.57 -12.35 and Stock-in-Trade (d) Employee Benefit Expense 85.40 99.43 62.33 161 .76 ( e) Fihance Cost 6.22 5.82 6.95 12.76 (f) Depreciation & Amortised Expense 18.80 1-7.07 9.79 26.86 ( g) Other Expenses 120.72 120 .33 74.15 194.47 Total Exoenses 2,728.30 2,166 .09 1,932.77 4,098 .86 Profit before exceptional and extraordinary items and tax v (Ill · IV) 601.45 494.59 473.11 967.70 VI Exceptional Items ' Prior Period Items Vil Profit before extraordinary items and tax (V - VI) 601.45 494.59 473.11 967.70 VIII CSR Provision IX Profit before tax (VII - VIII) 601.45 494.59 473.11 967.70 x Tax expense; (1) Current tax 152.61 124.49 119.08 243.57 (2) Deferred tax -1.22 0.39 0.39 ~ (3) Prior Period tax (4) Less: TDS f'rot 1t/(LossJ tor the penoa trom continuing operations XI (IX-X) 450.07 370.11 353.64 723.74 XII Profit/(loss) from discontinuing operations XIII Tax expense of discounting operations XIV Profit/(Lo ss) from Discontinuing ope rations (aJtertax) (XII-XIII) XIII Profit/(Loss) for the period (XI+ XIV) 450.07 370.11 353.64 723.74 XVI Earning per equ ity share of Rs.10 each (1) Basic 3.89 3.20 3.06 6.26 (2) Diluted 2.21 3.20 3.06 6.26 For Shelter Pharma Limited ~ ~~ # •, ' ~ @ / '"' ' Mustaqim N Sabugar ED ~ Chairmain & Managing Director ~~ + ) Shakil N Sabugar Whole Time Director DIN: 01456841 + 0- DIN: 01474868 '.<l •o @rned.a'O Place: Ahmedabad _ Date: 10/11/2025
Page 6
SHELTER PHARMA LIMITED CIN NO.: L24233GJ2007PLC051956 Standalone Unaudited Cash Flow Statement for the half year ended on September 30, 2025 (Amount In Lakhs) Particulars A) CASH FLOW FROM OPERATING ACTIVITIES Net Profit / (Loss ) Before Tax & Extra Ordin ary Items: Adjustments For : Deprec iation & Amortization Expe n se Prior Period Adju stment Deferred tax exp / income Fin ance Cost Non -operating income, (lntrest Received, etc) Operating Profit Before Working Capital Changes Adjustments For : (Increase)/ Decrease in Inventories (Increase)/ Decrease in Trade Receivables (Increase)/ Decrease in Short Term Loans & Advances (Increase)/ Decrease in Other Current Assets Increase/ (Decrease) in Trade Payable Increase/ (Decrease) Other Current Liabilities Increase/ (Decrease) Short term provision Increase/ (Decrease) Long' term provision Cash Generated From Operations Income Tax Paid Net Cash From Operating Activities B) CASH FLOW FROM INVESTING ACTIVITIES Pur ch ase of Fixed Assets Purc h ase of Shares & Funds Repayment of Lo·ng Term Loans & Advances Intrest Received Net Cash From Investing Activities C) CASH FLOW FINANCING ACTIVITIES Mone:Y Received against share warrants Proce eds of Security Premi u m Increa se /(Decrease) in Long term B orrowin gs Dividend Paid Prilimn ey Exp . (!PO Su bsidy ) Increase/ (Decrease) Short Term Borrowings i. ii. i+ii (A) (B) Net Cash From Financing Activities (C) Increase in Cash and. Cash Equivalents (D) (A)+(B)+(C) Cash and Cash Equivalents at the Beginning of the (E) Year Cash and Cash Equivalents at the End of the Year (D) +(E) Compon en ts of Cash and Cash Equivale nts: Cash on Hand Oth er Bank Balances Total Notes : For the half year Ended on 30.09.2025 (Un Audited) 601.45 18 .80 (2.24) (0.47) 617 .54 (385.24) (146 . 17) (202.22) 19.41 (45.52) 33. 15 (28.78) (755.38) 72.80 (210.63) (1 04 .22) (869.15) 0.47 (972 .91) 1,350.84 (8.88 ) 1.12 26.43 1 369 .51 185.97 341.99 527.96 82.91 44 5.05 527 .96 For the year ended on 31.03.2025 (Audited) 967.70 26.86 (0.55) 994.02 (296.62) (62.45) (182.30) 23.40 53.66 0.64 250.22 0.38 (213.06) 243 .57 537 .38 (265 .05) (448.29) 0.55 (712.79) 3 5.84 (38. 15) 4.89 10.84 13.42 (161.99) 503.98 341.99 77 .51 264.48 341.99 1) Th e cash flow statement h as bee n prepared in acco rdance with the requirement of Companies Act 20 13. 2) Figures in brackets indicate Cash Outfl ow For Shelter Pharma Limited ~ Must aqim N Sabug a r Chairmain & Managing Direc tor DIN: 01456841 Place: Ahmedabad Date: 10/11/2025 Shakil N Sabug ar Whol e Tim e Director DIN: 01474868
Page 7
E~R Shelter~ /\ Health & Happiness Explanatory notes to the Statement of Unaudited Standalone Financial Results for the half year ended 3Qth September, 2025 1. The above Unaudited Standalone Financial Results for the half year ended 30th September, 2025 have been prepared in accordance with the Accounting Standard prescribed under Section 133 of the Companies Act, 2013 read with Companies (Accounting Standards) Rules, as amended. These results have been Reviewed by the Audit Committee and approved by the Board of Directors of the company at their respective meeting held on November 10, 2025. 2. The Statutory Auditors have carried out a "Limited Review" of above Unaudited financial results of the company for the half year ended 30th September, 2025. 3. As per Accounting Standard 17 on "Segment Reporting" (AS 17), the company is engaged in Manufacturing of Pharmaceuticals. 4. There are no investor complaints received for the period under review. 5. The Earning per shares (EPS) has been computed in accordance with the accounting standard on earning per share. 6. The figures for the corresponding Previous year/period figure have been regrouped/rearranged Wherever necessary, to make them comparable . For Shelter Pharma Limited ~ Mustaqim N Sabugar Chairmain & Managing Director DIN: 01456841 Place: Ahmedabad Date: 10/11/2025 Shelter Pharma Limited Shakil ~ Sabugar Whole Time Director DIN: 01474868 Regd . Office & Works: Shelternagar , Opp. Bus Station , Himatnagar - 383 001 Gujarat , !NOIA. Phone : +91 -2772 296038 I CIN: L24233GJ2007PLC051956 Corporate Office: 501 , Sakar-4 , Ellisbridge , Opp. Town Hall, Ashram Road , Ahmedabad - 380 006, Gujarat , !NOIA. Phone : +91-9898 633551 Email: info@shelter.co.in
Page 8
~ CA Sahel N. Mendajiwala M. 98 98 98 5702 IND I A Mendajiwala & Co. Ref. No.01 Board of Directors, Shelter Pharma Limited Shelternagar, Nr.S.T. Bus Stand, Himmatnagar - 383001, Gujarat, India Chartered Accountant Sub: Report on Statement of Deviation and Variation on Utilization of Funds Raised through Preferentiallssue of Convertible Warrantsinto Equity Shares by the Shelter Pharma Limited till 3othseptember, 2025. Management's Responsibility for the Statement Date: The Management of the company is responsible for the preparation of the Annexure . This includes collection , collating and validation of data and presentat ion thereof in the Annexure and the design, implementation and maintenance of internal control relevant to the preparation of the Annexure that are free from material misstatement , whether due to fraud or error. The Management of the company is also responsible for the maintenance of proper books of account and other records and documents containing relevant details about Deviation and Variation in Utilization of Funds raised through Preferential Issue of Convertible Warrants into Equity Shares by the company. Auditor's Responsibility Our responsibility, for the purpose of this certificate is limited to certify the information containing in the Annexure on the basis of examination df the ,books of accounts, Statements and other relevant records and documents for the period ending 301h September, 2025 maintained by the company and produced before us for verification containing relevant details about the deviation and variation in Utilization of Funds Raised through Preferential Issue of Convertible Warrants into Equity Shares by the company . We conduct our examination of the Annexure in accordance with the Guidance Note on Reports or certificate for Special Purpose (the "Guidance Note") issued by the Institute of Chartered Accountant of India ("ICAI'') and Standard on Auditing specified under Section 143(10) of the companies Act 2013. The Guidance note requires that we comply with the ethical requirements of the Code of Ethics issued by the ICAI. We have complied with the relevant applicant requirement of the Standards on Quality Control (SQC) Quality control for firms that Performs Audits and reviews of Historical Financial Information, and other Assurance and Related Services Engagements. Opinion 539, 540, Sheetal Varsha, Mahavir Business Park, Jamalpur Cross Road, Behrampura, Ahmedabad -380 022. Phone : 079·25353444 E-mail: mendajiwala1011@yahoo.com
Page 9
Annexure Statement of Deviation and Variation on Utilization of Funds Raised Sr. Object disclosed in No. the Notice dated 26th June 2025 1. Working Capital Requirements Total For Mendajiwala& Co. Chartered Accountants FRN: 0135065W Amount received for object (Rs in Lakhs) 930.35 930.35 Name :M EDSOEL N MENDAJIWAI: Designation : Proprietor Membership No.: 146324 UDIN: Q5 14b32-Lt l?>IYIG-'f1N~i11 Date: -io 111 \ Q..1025 Place: Ahmedabad Actual Un Utilized Utilized Amount Amount (Rs in Lakhs) (Rs in Lakhs) 930.35 - 930.35 .. Remarks There is no deviation in the Objects for utilization of funds